Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04587934 · ClinicalTrials.gov registry record · NA
Time to Accurate Heart Rate on Neonatal Outcomes
A NA study of Premature Infant and Extreme Prematurity, sponsored by Sharp HealthCare.
- Completed
- Registry status
- NA
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT04587934: Completed NA study of Premature Infant and Extreme Prematurity, sponsored by Sharp HealthCare.
NCT04587934 is a NA study of Premature Infant and Extreme Prematurity that has completed, run by Sharp HealthCare. The registered enrollment target is 42 participants, below the 285-participant average among 9 other Premature Infant trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04587934, a NA study of Premature Infant and Extreme Prematurity, has completed, sponsored by Sharp HealthCare.
- COMPLETED
- Registry status
- NA
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this trial is to compare the time to first heart rate displayed for iRes Warmer with ResusView and using iRes Warmer without ResusView when used in the resuscitation (e.g. Cardiopulmonary resuscitation or breathing assistance) of premature newborns (23 to 32+6 weeks gestation).
Primary Outcome
Measure time from birth to heart rate displayed on monitor following lead placement
Conditions Studied
Interventions
- DEVICE iRes Warmer with ResusView
- OTHER iRes Warmer without ResusView
Study Locations (1)
California
- Sharp Mary Birch Hospital for Women and Newborns - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2021-02-01 |
| Est. Completion | 2021-12-10 |
| Phase | NA |
What the finished NCT04587934 record still lists
NCT04587934 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 285-participant average among 9 other Premature Infant trials with a reported enrollment target (85% lower).
The record links to 3 conditions, with Premature Infant appearing as the primary indexed condition, and to 2 interventions - of which iRes Warmer with ResusView is the first listed.
NCT04587934 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04587934 about?
NCT04587934 is a clinical study titled "Time to Accurate Heart Rate on Neonatal Outcomes". The goal of this trial is to compare the time to first heart rate displayed for iRes Warmer with ResusView and using iRes Warmer without ResusView when used in the resuscitation (e.g. Cardiopulmonary resuscitation or breathing assistance) of premature newborns (23 to 32+6 weeks gestation).
What is the current status of trial NCT04587934?
This trial is currently completed. It is a NA study. The enrollment target is 42 participants. The study started on 2021-02-01. Estimated completion is 2021-12-10.
What conditions does trial NCT04587934 study?
This clinical trial studies the following conditions: Premature Infant, Extreme Prematurity, Extremely Low Birth Weight.
What interventions are being tested in trial NCT04587934?
The interventions under investigation include: iRes Warmer with ResusView (DEVICE), iRes Warmer without ResusView (OTHER).
Who is sponsoring clinical trial NCT04587934?
This trial is sponsored by Sharp HealthCare, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04587934 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Premature Infant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04587934's enrollment target sits among peer trials
42 8th of 9 higher than 2 of 9 other Premature Infant trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Premature Infant trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Preventing Vulnerable Child Syndrome in the NICU With Cognitive Behavioral Therapy (PreVNT Trial)
RECRUITING · NA
-
Cycled Phototherapy
ACTIVE NOT RECRUITING · NA
-
Genesis Electrical Impedance Tomography (EIT): A Preliminary Study
RECRUITING
-
Growing Little PEAPODS Study
RECRUITING
-
Cincinnati Infant Neurodevelopment Early Prediction Study (CINEPS)
ACTIVE NOT RECRUITING
-
Ultrasound Assessment of BC in the NICU
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI